This trial is conducted in the United States of America (USA). The purpose of the trial is to compare the effect of Norditropin® using different dosing regimens in children suspected of growth hormone deficiency.

Inclusion Criteria:

• Clinically suspected GHD
• Height < -2.0 SDS
• Serum IGF-I less than or equal to -1.0 SDS
• Bone age less than or equal to 9 years for boys and less than or equal to 7 years for girls.
• Puberty Tanner Stage I

Exclusion Criteria:

• Previous use of growth hormone
• Growth retardation attributable to causes other than GHD (e.g. inborn errors of metabolism, primary bone disease, chromosomal disorders, etc.)
• Intrauterine growth retardation: birth weight < 3rd percentile.
• Administration of other growth-altering medications.
• Evidence of any malignancy or intracranial tumors.